Trials / Conditions / Recurrent Hepatocellular Carcinoma

Recurrent Hepatocellular Carcinoma

26 registered clinical trials studyying Recurrent Hepatocellular Carcinoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Suspended	Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing He NCT06968195	Roswell Park Cancer Institute	Phase 1
Recruiting	The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carc NCT06609850	Sun Yat-sen University	N/A
Withdrawn	Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally A NCT05327738	OHSU Knight Cancer Institute	Phase 2
Recruiting	Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant NCT05103904	Emory University	Phase 2
Active Not Recruiting	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484	National Cancer Institute (NCI)	Phase 1
Recruiting	Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119	Children's Oncology Group	Phase 1 / Phase 2
Terminated	Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer NCT04805788	Mayo Clinic	Phase 2
Unknown	Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC NCT04663035	Ming Zhao	Phase 2
Recruiting	Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC NCT04615143	Sun Yat-sen University	Phase 2
Active Not Recruiting	IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver NCT03655002	City of Hope Medical Center	Phase 1
Unknown	The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC NCT04800497	University of Milano Bicocca	—
Withdrawn	A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation NCT03634683	Lion TCR Pte. Ltd.	Phase 1 / Phase 2
Unknown	Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma NCT03609268	Second Affiliated Hospital, School of Medicine, Zhejiang University	N/A
Unknown	TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Tra NCT04677088	Xiaoshun He	Phase 1
Active Not Recruiting	Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder C NCT03257761	University of Southern California	Phase 1
Active Not Recruiting	Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer NCT03186898	NRG Oncology	Phase 3
Active Not Recruiting	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592	National Cancer Institute (NCI)	Phase 2
Terminated	Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Rad NCT02762266	Stanford University	Phase 3
Unknown	A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation NCT02719782	Lion TCR Pte. Ltd.	Phase 1
Completed	Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors NCT02143401	National Cancer Institute (NCI)	Phase 1
Completed	Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma NCT02613156	Sun Yat-sen University	—
Completed	Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion NCT02728219	Eastern Hepatobiliary Surgery Hospital	N/A
Completed	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820	Roswell Park Cancer Institute	Phase 1
Withdrawn	Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) NCT01318200	Accuray Incorporated	Phase 3
Completed	Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence NCT02447679	Chang Gung Memorial Hospital	Phase 2
Completed	Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Met NCT01015833	National Cancer Institute (NCI)	Phase 3